A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

Seattle Genetics, Inc.

Information provided by (Responsible Party):

Millennium Pharmaceuticals, Inc.

ClinicalTrials.gov Identifier:

NCT01578499

First received: March 27, 2012

Last updated: January 6, 2016

Last verified: January 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	July 2018
Estimated Primary Completion Date:	May 2016 (Final data collection date for primary outcome measure)